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Abstract
The aim of this study was to assess the ability of pre-and intraoperative parameters, to predict the risk of perioperative complications
after robot-assisted laparoscopic simple enucleation (RASE) of renal masses, and to evaluate the rate of trifecta achievement of this
approach stratifying the cohort according to the use of ischemia during the enucleation.
From April 2009 to June 2016, 129 patients underwent RASE at our Institution. We stratiﬁed the procedures in 2 groups: clamping
and clamp-less RASE. After RASE, all specimens were retrospectively reviewed to assess the surface–intermediate–base (SIB)
scoring system. Patients were followed-up according to the European Association of Urology guidelines recommendations. All pre-,
intra-, and postoperative outcomes were prospectively collected in a customized database and retrospectively analyzed.
A total of 112 (86.8%) patients underwent a pure RASE and 17 (13.2%) had a hybrid according to SIB classiﬁcation system. The
mean agewas 61.17 years. In 21 patients (16.3%), complications occurred, 13 (61.9%) were Clavien 1 and 2, while 8were Clavien 3a
and b complications. Statistical signiﬁcant association with complications was found in patients with American Society of
Anestesiology (ASA) score 3 (44.5%, P= .04), longer mean operative time (OT) 195 versus 161.36minutes (P=.03), mean
postoperative hemoglobin (Hb) 10.1 versus 11.8 (P<.001), and mean DHb 3.59 versus 2.18 (P<.001). In multivariate logistic
regression, only longer OT and DHbwere statistical signiﬁcant predictive factors for complications. In sub-group analysis, clamp-less
RASE was safe in terms of complications (14.1%), positive surgical margins (1.3%), and mid-term local recurrence (1.3%). Although
in this approach there is higher EBL (P= .01), this had no impact on DHb (P= .28). A clamp-less approach was associated with a
higher rate of SIB 0 (71.8% vs 51%, P= .02), higher trifecta achievement (84.6% vs 62.7%, P= .004), and better impact on serum
creatinine (mean 0.83 vs 0.91, P= .01).
RASE of renal tumors is a safe technique with very good postoperative outcomes. Complication rate is low and associated with
ASA score >3, longer OT, and DHb. RASE is suitable for the clamp-less approach, which allows to perform easier the pure
enucleation (SIB 0) and to obtain higher rates of trifecta outcomes.
Abbreviations: ASA= American Society of Anestesiology, BMI= bodymass index, EAU= European Association of Urology, EBL
= estimated blood loss, NSS= nephron sparing surgery, OT= operatory time, PADUA= preoperative aspects and dimensions used
for an anatomical, PN = partial nephrectomy, PSM = positive surgical margins, RASE = robot-assisted simple enucleation, RCC =
renal cell carcinoma, SE = simple enucleation, SIB = surface–intermediate–base, SM = surgical margin, WIT = warm ischemia time.
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Despite the nephron sparing surgery’s (NSS) concepts are well
known, no overall accepted consensus yet exists regarding the
optimal width of normal parenchyma that should surround
the tumor to both avoid local recurrence and loss of renal
function.[1–5]
In order to further increase the amount of normal renal tissue
sparedduringNSS, tumor simple enucleation (SE)wasproposed as
a minimal partial nephrectomy (PN).[1] The presence of a
continuous, ﬁbrous capsule composed of dense connective ﬁbrous
tissue surrounded by healthy tissue with a median thickness of 1
mm represents the pathologic rationale, which allows avoiding the
tumor-surrounding healthy tissue removal without undermining
the oncological radicality.[2–5] As a result, tumor SE should not be
in contrast with the European Association of Urology (EAU)
guidelines which state the maintenance of a “minimal” tumor-free
surgical margin (SM), sufﬁcient to avoid local recurrence, without
specifying its exact thickness.[6]
Tumor SE is performed in an avascular plane (if the perforating
vessels for the tumor are excluded), allowing to carry out the
procedure also without clamping the renal artery, hence without
ischemia.[3,4,7] Nonetheless, as shown for open surgery, dimen-
sion, anatomical aspects of the tumor as well as vascular variants
of the renal blood supply may increase the procedure complexity
and difﬁculty, with a possible impact on the complication rate in a
robot-assisted approach, too.
For a better comparison of different surgical techniques, the
achievement of trifecta outcome was described[8] as the
simultaneous obtainment of negative SMs, renal function
preservation, and no urological complications.
The aim of this study was to assess the ability of pre-and
intraoperative parameters (including the preoperative aspects and
dimensions used for an anatomical preoperative aspects and
dimensions used for an anatomical (PADUA) scoring system), to
predict the risk of perioperative complications after robot-assisted
laparoscopic simple enucleation (RASE) of renal masses, and to
evaluate the rate of trifecta achievement of this approach stratifying
the cohort according to the use of ischemia during the enucleation.2. Methods
SE was ﬁrst performed in our Divisions in November 2011 and it
accounts for 38% (129) from all the robotic NSS procedures
done between April 2009 and June 2016 in our department (342
in total). The preoperative diagnostic workup included contrast
enhanced computer tomography (CT) scan, blood analyses, and
anesthesiology evaluation (including American Society of
Anestesiology [ASA] score) in order to draw out patients suitable
to undergo this type of surgery using the robot-assisted
laparoscopic approach. A mass biopsy was performed anytime
imagistic information (contrast enhancement features and
growth rate)[9] could not rule out for sure the malignant nature
of the mass: it was the case of 45 (34.9%) patients. All tumors
were scored according to the PADUA scoring system.[10]
After having received Institutional Review Board approval, we
carried out the retrospective chart review of the 129 patients who
underwent RASE. We stratiﬁed RASE in 2 groups, clamping and
clamp-less RASE, at our institutions during the considered period.
2.1. Patient selection
All treatment options available in our institutions, including
surveillance or percutaneous tumor ablation, were discussed with2the patients. Patients receiving (and accepting) surgical indication
were ﬁrst evaluated if eligible for robotic surgery. After more than
2 years of experience with robot-assisted “classic PN,”[11] simple
tumor enucleation was adopted as an alternative NSS technique
and preferred to the “classic PN” every time that after the kidney
preparation, the mass revealed easily to be approached.
Successively, larger and more complex (i.e., higher renal score)
tumors underwent enucleation; in all cases, the intention was to
perform the procedure without clamping the artery unless the
case was judged at a risk of bleeding or if relevant blood loss (BL)
occurred during the procedure and (deferred) artery clamping
was however required.
Tumor histology was performed according to the 2004 World
Health Organization criteria[12] and grade classiﬁcation followed
the Fuhrman scheme. Surgical staging was according to the
tumor, node, metastasis system.[13] Disease relapse was deﬁned as
any local recurrence (retroperitoneal or renal fossa) or distant
metastasis biopsy-proven renal cells carcinomas RCCs. Recur-
rences in contralateral kidney were considered as second
primaries. All specimen were retrospectively reviewed to score
the thickness of healthy parenchyma visually evident on the
superﬁcial surface of the tumor according to the surface–
intermediate–base (SIB) scoring system,[14] conﬁrming that in all
cases enucleation was performed (SIB score sum 0–1).2.2. Surgical technique
All procedureswere performed using the transperitoneal approach
with da Vinci Si system. First, the renal pedicle was dissected out
and the artery well exposed to enable prompt clamping in case of
excessive bleeding during tumor excision, in case of clamp-less
intention. Intraoperatoty ultrasound was performed in all cases.
After having had dissected out the kidney and sweeped the
perinephric fat away from the tumor, the capsule was sharply
incised (using the monopolar scissors coagulation) circumferen-
tially or hemi-circumferentially (Fig. 1A) starting from the passage
between lesion and the healthy renal tissue. Once the tumor
pseudo-capsulewas seenandreached, the tumorwasenucleatedby
blunt dissection, with no visible rim of normal parenchyma. The
development of the cleavage between the tumor and the healthy
tissue was performed in 2 different manners: the classic way,[11]
surrounding the mass and conducting the dissection until the
deepest part of the tumor is reached and detached from the tumor
bed or according to our previously described “beer-bottle-opener
technique”[15] using blunt dissection and adequate traction. The
cleavage plane between tumor and healthy tissue is thus reached,
starting from the hemi-circumferential capsule incision (Fig. 1B)
and developed toward the deepest part of the tumor; the dissection
is carried out under direct vision (Fig. 1C) and perforating vessels,
clipped. After the deepest part of the tumor bed is reached, the
cleavage plane is developed toward the posterior half-circumfer-
ence and ﬁnally the tumor completely excised (Fig. 1D).
3/0 poliglecaprone running sutures secured with resorbable
Lapra-Ty clips were used for closure of the renal medulla.
Re-approximation of the cortical parenchyma was performed
with 2/0 polyglactin simple mattress sutures, secured with sliding
Weck Hem-o-lok clips and reinforced with Lapra-Ty clips
(Ethicon, Cincinnati, OH).
After renal reconstruction, hemostasis was again ensured with
careful inspection of the surgical bed under low insufﬂations
pressure. The specimen was extracted, the gross margins of the
tumor were inspected, and the specimen was sent to the
pathology laboratory for permanent section.
Figure 1. Our technique for SE. (A) Half-circumference capsule incision; (B) once reached the tumor surface, the cleavage is developed by blunt dissection; (C) the
visual control of the tumor bed; (D) the enucleation is concluded by cutting the posterior attachment with the capsule (dotted line). SE = simple enucleation.
Matei et al. Medicine (2017) 96:18 www.md-journal.comIntraoperatory features as well as postoperative complications
were recorded and scored according to the Clavien system.Overall
operatory time (OT) (as surrogateof the proceduredifﬁculty), EBL,
hemoglobin (Hb) loss, creatinine level (between preoperatory and
latest recorded follow-up, median 25 months) and nutritional
status (body mass index [BMI]) were also recorded.
Patients were followed according to the guidelines recommenda-
tions[16] and institutional protocol, including clinical examination,
laboratory blood tests (hemogram, renal function examination),
urine analysis, CT scan (thorax and abdomino-pelvic) or abdominal
MRI, and chest x-ray, at 3 and 9 months after surgery and
afterwards annually for 5 years and every 2 years thereafter.
Three types of analysis were carried out: the correlation
between patients characteristics (such as PADUA score, ASA
score, and BMI) and complications after RASE; the correlation
between intraoperatory parameters (such as OT and blood loss)
and complication rates; and outcomes of clamp-less RASE were
compared with those of clamping RASE, including the
simultaneous achievement of the 3 goals of NSS, that is, negative
SMs, functional preservation, and complication-free recovery,
known as trifecta outcome.[17]2.3. Statistical methods
Associations of postoperative complications with categorical
variables were assessed using the chi-square tests, while differ-
ences in means of continuous variables were analyzed using the t
test. Logistic regression analysis was performed to assess the
association of predictive factors with complications. Sub-group
analyses according to clamping technique were also done. All P
values were 2-sided, and statistical signiﬁcance was deﬁned as a
P<.05. Statistical analyses were performed using Stata 11.0
statistical software (Stata Corp., College Station, TX).33. Results
3.1. Patients characteristics and association with
complications after RASE
A total of 129 patients underwent RASE in our tertiary
department. Out of these, 112 (86.8%) had a pure SE and 17
(13.2%) had hybrid SE according to SIB classiﬁcation system.
The mean age was 61.17 years and most of them were males
(67.4%). Complications were experienced by 21 patients
(16.3%), 13 (61.9%) patients had Clavien 1 and 2 complications
(8 (61.5%) had anemia, 2 (15.4%) hematoma, and 1 (7.7%)
hematuria, atrial ﬁbrillation, and chylous ascites), and 8 patients
had Clavien 3a and b complications (5 urinary ﬁstulas and 1 had
tumor bed bleeding, hemicholectomy, and trocar port bleeding,
respectively). The mean tumor diameter revealed on CT scan was
33.79mm, in concordance with mean histological diameter of the
tumor, that is, 33.62mm, but with higher mean diameter in
patients who experienced complications, that is, 37.54mm onCT
scan.Most patients had tumors on the right side (74, 57.4%), but
complications were more frequent in patients with tumors on the
left side (18.2%, P= .61). Complications were not associated
with PADUA score nor with PADUA complexity classiﬁcation
(P= .14 and .09, respectively), instead we noticed higher
complication rates in patients with PADUA score >8 and in
those classiﬁed as high complex with 42.9% patients with
complications.
Complications were more frequent and a statistical signiﬁcant
association was found in patients with ASA score 3 (44.5%,
P= .04). Complications were also associated with a longer mean
OT (195 vs 161.36min, P= .03), mean postoperatory Hb
(10.1 vs 11.8, P<.001), and mean DHb. (3.59 vs 2.18,
P<.001), but were not associated with mean estimated blood
loss (EBL) (P= .67) (Table 1).
Table 1
Association of clinic-pathologic and functional parameters with complications in 129 patients who underwent RASE.
Parameter All cohort No complications Complications P value
Age (mean), y 61.17 60.7 63.6 .22
Gender
Female 42 (32.6) 34 (80.9) 8 (19.1) .55
Male 87 (67.4) 73 13 (14.9)
Diameter CT (mean) 33.79 33.01 37.54 .19
Diameter histology (mean) 33.62 33.27 35.38 .57
Side
Left 55 (42.6) 45 10 (18.2) .61
Right 74 (57.4) 63 (85.1) 11 (14.9)
PADUA score
6 43 (33.3) 39 (90.7) 4 (9.3) .14
7 43 (33.3) 36 (83.7) 7 (16.3)
8 24 (18.6) 19 (79.2) 5 (20.8)
9 12 (9.3) 10 (83.3) 2 (16.7)
10 3 (2.3) 1 (33.4) 2 (66.6)
11 2 (1.6) 2 (100) 0
12 2 (1.6) 1 (50) 1 (50)
PADUA complexity
Low 86 (66.7) 75 (87.2) 11 (12.8) .09
Intermediate 36 (27.9) 29 (80.5) 7 (19.5)
High 7 (5.4) 4 (57.1) 3 (42.9)
ASA score
1 75 (58.1) 63 (84) 12 (16) .04
2 45 (34.9) 40 (88.8) 5 (11.2)
3 9 (7) 5 (55.5) 4 (44.5)
BMI (mean) 26.68 26.73 26.43 .73
OT (mean), min 166.83 161.36 195 .03
EBL (mean), mL 265.24 272 230 .67
pT stage
Benign 19 (14.7) 14 (73.7) 5 (22.3) .67
1a 71 (55) 60 (84.5) 11 (15.5)
1b 21 (16.3) 18 (85.7) 3 (14.3)
2a 2 (1.6) 2 (100) 0 (0)
3a 10 (7.7) 8 (80) 2 (20)
Unclassiﬁed 6 (4.7) 6 (100) 0 (0)
Fuhrman grade
0 19 (14.7) 14 (73.7) 5 (22.3) .69
1 17 (13.2) 14 (82.3) 3 (17.7)
2 73 (56.6) 62 (84.9) 11 (15.1)
3 13 (10.1) 12 (92.3) 1 (7.7)
unclassiﬁed 7 (5.4) 6 (85.7) 1 (4.3)
SIB
0 82 (63.6) 68 (82.9) 14 (17.1) .88
1 30 (23.2) 26 (86.7) 4 (13.3)
2 17 (13.2) 14 (82.3) 4 (17.7)
CKD baseline
Stage 0–1 102 (79) 86 (84.3) 16 (15.7) .72
Stage 2–3 27 (21) 22 (81.4) 5 (18.6)
CKD
Stage 0–1 103 (79.8) 87 (84.4) 16 (17.6) .64
Stage 2–3 26 (20.2) 21 (80.8) 5 (19.2)
eGFR baseline (mean) 70.11 69.56 72.94 .27
eGFR (mean) 68.94 68.41 71.71 .23
Serum Cr baseline (mean) 0.90 0.89 0.94 .31
Serum Cr (mean) 0.86 0.85 0.90 .36
DCr (mean) -0.03 -0.03 -0.04 .83
Hb baseline (mean) 14.03 14.1 13.7 .23
Hb postop. (mean) 11.54 11.82 10.1 <.001
DHb (mean) 2.41 2.18 3.59 <.001
LOS (mean), d 4.74 4.52 5.85 <.001
ASA=American Society of Anesthesiologist score; BMI= body mass index, CKD= chronic kidney disease, Cr= creatinine, CT= computer tomography, EBL= estimated blood loss, eGFR= estimated glomerular
ﬁltration rate, Hb=hemoglobin, LOS= length of stay, OT= operation time, PADUA=Preoperative Aspects and Dimensions Used for an Anatomical classiﬁcation, RASE = robot-assisted simple enucleation,
SIB= surface–intermediate–base.
Bold values signify statistically signiﬁcant.
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In univariate analysis high PADUA complexity (odds ratio [OR]
5.11, P= .04), longer OT (OR 1, P= .03), and DHb. (OR 1.94,
P<.001) were statistical signiﬁcant predictive factors for
complications. In multivariate logistic regression, only OT and
DHb retain a statistical signiﬁcant value as independent
predictors of complications after RASE (Table 2).3.3. Safety of clamp-less RASE compared with clamping
RASE
When we performed subgroup analysis according to clamping
approach, we noticed that clamp-less RASE is safe in terms of
PADUA score, PADUA complexity of tumors, ASA score of
patients, OT, complications (14.1%), positive surgical margins
(PSM) (1.3%), and mid-term local recurrence (1.3%). Instead, in
these approaches, patients may lose more blood (P= .01), but
with a low rate of postoperatory blood transfusion (8.9%,
P= .02) and with no impact on DHb. (P= .28) and with a slightly
lower length of hospital stay (4.47 vs 5.15 mean days, P<.001).
The clamp-less approach was associated with a higher rate of SIB
0 achievement (71.8% vs 51%, P= .02) and with higher trifecta
achievement (84.6% vs 62.7%, P= .004). The clamp-less
approach was found to have a better impact on serum creatinine
too (mean 0.83 vs 0.91, P= .01), but with no statistical
signiﬁcance as far as estimated glomerular ﬁltration rate at last
follow-up was concerned (Table 3).4. Discussion
Tumor SE should be considered as an attempt aimed to improve
the results of PN by decreasing at minimum the amount of
healthy renal tissue to be removed.[6,18] Moreover, by conducting
the dissection through the natural cleavage, which is an avascular
plane, the renal artery clamping might be omitted or eventually
deferred.[8,12]
Even if in his paper Ficarra et al[10] observed that in
multivariate analysis PADUA scores were independent predictors
of the occurrence of any grade of complications, they also draw
the attention on a major limit of their study, that is, the lack of
laparoscopically treated patients in his series.Table 2
Univariate and multivariate logistic regression for predicting complic
Variable
Univariate
OR CI P
Gender 0.74 0.28–1.96
Age (cont.) 1.03 0.98–1.08
PADUA complexity Ref.
Intermediate 1.64 0.58–4.65
High 5.11 1.00–25.97
Side 0.78 0.3–2
Diameter CT (cont.) 1 0.97–1.03
OT (cont.) 1 1–1.01
EBL (cont.) 0.99 0.99–1
ASA score Ref.
2 0.65 0.21–2
3 4.2 0.98–17.94
Delta Hb (cont.) 1.94 1.36–2.74
ASA=American society of anesthesiologist, CI = conﬁdence interval, CT= computer tomography, EBL=
Aspects and Dimensions Used for an Anatomical classiﬁcation.
Bold values signify statistically signiﬁcant.
5Unfortunately, none of the various analysis of the results of the
group of Florence, both in open or in robotic surgery, take into
account an attempt to validate this renal score in this peculiar
setting.[3–5,7] They only concluded that the robotic approach can
achieve better surgical results by reducing the need for clamping,
warm ischemia time (WIT), EBL, and length of stay, mainly due
to a clearly lower complication rate.[7]
In our series, overall complication rate was similar to
previously mentioned experiences (16.3%), despite that our
cohort included patients with higher mean diameter and higher
PADUA score.
Ours seems the ﬁrst study testing the value of the PADUA renal
score in predicting the complication occurrence in this setting
(i.e., robotic SE) (Table 2), and we noticed that only OT and dHb
are independent predictive factor for predicting complications. In
case of OT more than 195minutes, one should carefully manage
the patient as it has a higher risk of complication occurrence,
same as the loss of 3.5 point of postoperatory Hb increase with
2-fold the risk of complications.
Also, patients with high PADUA complexity score might
experience higher rates of complications with an OR of 8.5. On
the other hand, Serni et al[18] in a cohort of 96 patients with high
complex PADUA score tumors reported a high complication rate
of 26.1% and included only 20 patients with RASE, thus, it seems
that the robotic approach might not be ﬁt for high PADUA score
tumors.
The main criticism against tumor SE is the higher risk of PSMs
as a result of conducting the dissection in the natural cleavage
plane.
The need of a safety margin during PN was arbitrary chosen
in 1950 by Vermooten[19] and its thickness became a debated
issue as many studies demonstrated that the “safety” should be
guaranteed by as less as 1mm of healthy tissue surrounding the
tumor and even by SE.[1] This more extensive NSS approach,
avoiding the tumor-surrounding healthy tissue removal, was
ﬁrst performed and advocated by Carini et al[1] in open surgery.
The group of Florence ﬁrst provided the pathologic rationale of
this minimal PN, describing the presence a continuous, ﬁbrous
capsule composed of dense connective ﬁbrous tissue surrounded
by healthy tissue with a median thickness of 1mm with signs of
chronic inﬂammation.[2] As a result, SE should not contrast the
EAU requirement of a “minimal healthy tissue layer” sufﬁcient toations in 129 patients that underwent RASE.
Multivariate
value OR CI P value
.55 0.4 0.12–1.34 .13
.22 1.03 0.97–1.1 .23
Ref.
.94 0.99 0.24–4.08 .99
.04 8.5 0.87–82.2 .06
.61 0.68 0.21–2.25 .53
.56 0.97 0.93–1.01 .27
.03 1.01 1–1.02 .04
.67 0.99 0.99–1 .051
Ref.
.45 0.46 0.12–1.8 .51
.053 1.66 0.23–11.82 .61
<.001 2.32 1.43–3.76 .001
estimated blood loss, Hb=hemoglobin, OR = odds ratio, OT=operation time, PADUA=Preoperative
Table 3
Patients characteristics and association with clinic, pathologic, and functional parameters in the 2 groups (clamp-less and no-clamp-less).
Parameter All cohort, n = 129 Group 1 clamping, n = 51 Group 2 clamp-less, n = 78 P value
Age (mean), y 61.17 60.47 61.62 .52
Gender
Female 42 (32.6) 15 (35.7) 27 (64.3) .53
Male 87 (67.4) 36 (41.4) 51 (58.6)
Diameter CT (mean) 33.79 35.92 32.39 .18
Diameter histology (mean) 33.62 34.23 33.21 .71
Side
Left 55 (42.6) 24 (31.2) 31 (68.8) .41
Right 74 (57.4) 27 (36.5) 47 (63.5)
PADUA score
6 43 (33.3) 13 (30.2) 30 (69.8) .21
7 43 (33.3) 22 (51.2) 21 (48.8)
8 24 (18.6) 9 (37.5) 15 (62.5)
9 12 (9.3) 3 (25) 9 (75)
10 3 (2.3) 1 (33.4) 2 (66.6)
11 2 (1.6) 1 (50) 1 (50)
12 2 (1.6) 2 (100) 0 (0)
PADUA complexity
Low 86 (66.7) 35 (68.6) 51 (65.4) .46
Intermediate 36 (27.9) 12 (23.6) 24 (30.7)
High 7 (5.4) 4 (7.8) 3 (3.9)
ASA score
1 75 (58.1) 31 (60.8) 44 (56.4) .78
2 45 (34.9) 16 (31.4) 29 (37.2)
3 9 (7) 4 (7.8) 5 (6.4)
BMI (mean) 26.68 27.17 26.36 .22
OT (mean), min 166.83 159.58 171.57 .31
EBL (mean), mL 265.24 151.41 339.66 .01
Transfusions 9.3% 9.8% 8.9% .02
pT stage
Benign 19 (14.7) 11 (57.8) 8 (42.2) .16
1a 71 (55) 25 (35.2) 46 (64.8)
1b 21 (16.3) 9 (42.9) 12 (57.1)
2a 2 (1.6) 1 (50) 1 (50)
3a 10 (7.7) 5 (50) 5 (50)
Unclassiﬁed 6 (4.7) 0 (0) 6 (100)
Fuhrman grade
1 17 (15.4) 7 (41.2) 10 (58.8) .31
2 73 (66.4) 27 (41.1) 46 (58.9)
3 13 (11.8) 5 (38.5) 8 (61.5)
Unclassiﬁed 7 (6.4) 1 (14.3) 6 (85.7)
SIB
0 82 (63.6) 26 (31.7) 56 (68.3) .02
1 30 (23.2) 18 (60) 12 (40)
2 17 (13.2) 7 (41.2) 10 (58.8)
PSM no. % 2 (1.55) 1 (1.9) 1 (1.3) .09
Complications 17% 21.6% 14.1% .27
Trifecta 76% 62.7% 84.6% .004
Local rec. 0.8% 0% 1.35% .42
CKD baseline
Stage 0–1 102 (79) 39 (76.5) 63 (80.8) .55
Stage 2–3 27 (21) 12 (23.5) 15 (19.2)
CKD
Stage 0–1 103 (79.8) 40 (78.4) 63 (80.8) .74
Stage 2–3 26 (20.2) 11 (21.6) 15 (19.2)
eGFR baseline (mean) 70.11 68.70 71.03 .31
eGFR (mean) 68.94 68.05 69.52 .48
Serum Cr baseline (mean) 0.90 0.90 0.90 .97
Serum Cr (mean) 0.86 0.91 0.83 .01
DCr (mean) -0.03 0.01 –0.006 <.001
Hb baseline (mean) 14.03 14.08 13.99 .72
Hb postop. (mean) 11.54 11.71 11.43 .34
DHb (mean) 2.41 2.24 2.52 .28
LOS (mean), d 4.74 5.15 4.47 .003
ASA=American society of anesthesiologist score, BMI=body mass index, CKD= chronic kidney disease, Cr= creatinine, CT= computer tomography, EBL= estimated blood loss, eGFR= estimated glomerular
ﬁltration rate, Hb=hemoglobin, LOS= length of stay, OT= operation time, PADUA=Preoperative Aspects and Dimensions Used for an Anatomical classiﬁcation, PSM=positive surgical margins,
SIB= surface-intermediate-base.
Bold values signify statistically signiﬁcant.
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Matei et al. Medicine (2017) 96:18 www.md-journal.comguarantee the surgical radicality and to avoid local relapse. The
same group proposed the SIB score in order to standardize the
terminology to describe the NSS technique and to facilitate
outcome assessments and comparisons of surgical series.[14]
Nevertheless, in the open series,[1,3] they report no PSM, and in
their robotic experience, the PSM reported rate was 2.8%.[7] In
our series, the rate was lower (1.5%) even if there are at least 2
major differences between the 2 series: the percentage of benign
lesions (17.7% vs 14.7%) and the percentage of clamp-less
procedures (33.9% vs 60.5%). In fact, we choose this approach
mainly to be performed without clamping or with a deferred
pedicle clamping.
The use of trifecta outcome further contributes to better deﬁne
and compare different surgical approaches. As previously shown,
trifecta outcomes improved in the robotic and laparoscopic
approach due to the reduction of PSM and zero ischemia
approach.[17,20] RASE further contributes in improving the
trifecta rate achievement.
The question if the PSM rate may be a satisfactory, oncologic
surrogate endpoint is still a matter of debate: some studies have
demonstrated no association between SMs status after PN of
small renal masses and recurrence of RCCs,[21,22] while others
suggest that in high-risk tumors, PSM might actually have a
clinical signiﬁcance,[23] in a very recent meta-analysis,[24] the
authors while arguing a noninferiority of SE compared with the
standard PN, note an association between PSM rate and disease
recurrence.
As shown before in the robotic SE published series, the rate of
procedures performed without WI is clearly higher,[7] than in
open setting.[3]
Zero ischemia was also associated with lower serum creatine at
last follow-up. Despite some reports doubt about the renal
function beneﬁt of 0 ischemia surgery, as its clinical consequence
should be little or inconsistent,[25] we ﬁrmly believe that avoiding
(where possible) renal pedicle clamping may show important
advantages on renal function preservation as was shown in a
similar cohort of 49 patients in a multi-institutional study.[26]
Excluding the potential effect of an unknown (as unpredictable)
WIT on the renal function, the decision for an off-clamping
approach should gradually determine (depending also on the
surgeon’s expertise) to avoid the dissection of the vascular pedicle
elements which will translate in lower OT and thus a decreased
risk of blood loss.
Limitations of this study include those inherent to a single-
institution, retrospective study, even if a mid-term follow-up.
Another bias of the study may refer to the OT, which might be
inﬂuenced by the learning curve of the surgeons and the fact that
our department is a teaching institution in which residents and
young specialists learn robotics. Although multiple patient and
tumor factors were included in our multivariable analysis,
unmeasured confounders and competing risk factors for
complications were not evaluated for in this analysis. As a
result, prospective, multicentric, and long-term follow-up studies
are required to conﬁrm the promising published data.5. Conclusions
RASE of renal tumors is a safe technique with very good
postoperative outcomes. Complication rate is low and associated
with ASA score>3, longerOT, andDHb. RASE is suitable for the
clamp-less approach, which allows to perform the pure
enucleation (SIB 0) easily and to obtain higher rates of trifecta
outcomes.7Acknowledgment
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